Perazodin 100mg coated tablets

Страна: Мальта

мова: англійська

Джерело: Medicines Authority

Активний інгредієнт:

DIPYRIDAMOLE

Доступна з:

Remedica Limited Limassol Industrial Estate, Aharnon Street, 3056 Limassol, Cyprus

Код атс:

B01AC07

ІПН (Міжнародна Ім'я):

DIPYRIDAMOLE 100 mg

Фармацевтична форма:

COATED TABLET

Склад:

DIPYRIDAMOLE 100 mg

Тип рецепту:

POM

Терапевтична области:

ANTITHROMBOTIC AGENTS

Статус Авторизація:

Authorised

Дата Авторизація:

2006-12-29

інформаційний буклет

page 1 of 5
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
PERAZODIN 25 MG COATED TABLETS
PERAZODIN 75 MG COATED TABLETS
PERAZODIN 100 MG COATED TABLETS
Dipyridamole
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This
includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. What Perazodin is and what it is used for
2. What you need to know before you take Perazodin
3. How to take Perazodin
4. Possible side effects
5. How to store Perazodin
6. Contents of the pack and other information
1.
WHAT PERAZODIN IS AND WHAT IT IS USED FOR
The name of your medicine is Perazodin. It contains a substance called
dipyridamole. This
belongs to a group of medicines called ‘anti-thrombotic agents’,
which are used to help
stop blood clots forming.
Perazodin helps stop blood clots which may occur if you have had your
heart valves
replaced.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PERAZODIN
DO NOT TAKE PERAZODIN
• if you are allergic (hypersensitive) to dipyridamole or to any of
the other ingredients of
this medicine
(listed in section 6).
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking Perazodin if:
• you have angina or other heart problems (including heart valve or
circulation problems)
or have had a recent heart attack.
• you have myasthenia gravis (a rare muscle problem).
• you have any bleeding problems.
page 2 of 5
• you are pregnant or planning to become pregnant or are
breast-feeding.
• you have been told by your doctor that you have an intolerance to
some sugars.
If you are not sure if any of the above apply to you, talk to your
doct

Характеристики продукта

Page 1 of 9
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
Perazodin 100 mg coated tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Perazodin 100 mg coated tablets: Each coated tablet contains 100 mg
dipyridamole.
Excipient(s) with known effect
This product contains 53.6 mg lactose monohydrate and 95.099 mg
sucrose.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Coated tablet.
White, round, coated tablets.
4. CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
An adjunct to oral anti-coagulation for prophylaxis of
thrombo-embolism associated with
prosthetic heart valves.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_ _
_Adults: _
300-600 mg daily in three or four doses.
_Children: _
Perazodin is not recommended for children.
_ _
Perazodin should usually be taken before meals.
Page 2 of 9
Method of administration
Oral administration.
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substance(s) or to any of the
excipients listed in section
6.1.
In case of rare hereditary conditions that may be incompatible with an
excipient of the product
(please refer to ‘Special warnings and precautions for use’) the
use of the product is
contraindicated.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Among other properties, dipyridamole acts as a vasodilator. It should
be used with caution in
patients
with
severe
coronary
artery
disease,
including
unstable
angina
and/or
recent
myocardial infarction, left ventricular outflow obstruction or
haemodynamic instability (e.g.
decompensated heart failure).
Patients being treated with regular oral doses of Perazodin should not
receive additional
intravenous dipyridamole. Clinical experience suggests that patients
being treated with oral
dipyridamole who also require pharmacological stress testing with
intravenous dipyridamole,
should discontinue drugs containing oral dipyridamole for twenty-four
hours prior to stress
testing.
In patients with myasthenia gravis, readjustment of therapy may be
necessary after changes in
dipyridamo